See the DrugPatentWatch profile for loratadine
Loratadine Phenylephrine Combinations: A Patent Analysis
H1. Introduction
Loratadine phenylephrine combinations are a type of over-the-counter (OTC) medication used to relieve symptoms of allergies and colds. These medications combine the antihistamine loratadine with the decongestant phenylephrine to provide relief from congestion, runny nose, and itchy eyes. In this article, we will explore the patents that cover loratadine phenylephrine combinations.
H2. Background
Loratadine is a non-sedating antihistamine that was first approved by the US FDA in 1993. Phenylephrine, on the other hand, is a decongestant that has been used for decades to relieve nasal congestion. The combination of these two active ingredients was first introduced in the early 2000s, and since then, several patents have been granted to cover these combinations.
H3. Patents Covering Loratadine Phenylephrine Combinations
According to DrugPatentWatch.com, a leading provider of pharmaceutical patent information, there are several patents that cover loratadine phenylephrine combinations. Some of the key patents include:
* US Patent 6,455,637: This patent, granted in 2002, covers a method of treating allergies and colds using a combination of loratadine and phenylephrine. The patent is owned by Schering-Plough Corporation, which is now a part of Merck & Co.
* US Patent 6,645,102: This patent, granted in 2003, covers a pharmaceutical composition comprising loratadine and phenylephrine. The patent is owned by Schering-Plough Corporation.
* US Patent 7,101,576: This patent, granted in 2006, covers a method of treating allergies and colds using a combination of loratadine and phenylephrine in a single tablet. The patent is owned by Merck & Co.
H4. Patent Expiration
The patents covering loratadine phenylephrine combinations are set to expire in the coming years. According to DrugPatentWatch.com, the patents are expected to expire as follows:
* US Patent 6,455,637: Expiration date: March 2024
* US Patent 6,645,102: Expiration date: June 2024
* US Patent 7,101,576: Expiration date: September 2025
H5. Generic Competition
The expiration of these patents is expected to lead to generic competition in the market. According to a report by the Generic Pharmaceutical Association, the market for loratadine phenylephrine combinations is expected to be highly competitive, with several generic manufacturers already having filed ANDAs (Abbreviated New Drug Applications) with the FDA.
H6. Market Impact
The expiration of these patents is expected to have a significant impact on the market for loratadine phenylephrine combinations. According to a report by Euromonitor International, the market for OTC allergy medications is expected to grow at a CAGR of 4.5% from 2020 to 2025. The entry of generic manufacturers into the market is expected to increase competition and drive prices down.
H7. Conclusion
In conclusion, the patents covering loratadine phenylephrine combinations are set to expire in the coming years, leading to generic competition in the market. The expiration of these patents is expected to have a significant impact on the market for OTC allergy medications.
H8. Key Takeaways
* The patents covering loratadine phenylephrine combinations are set to expire in the coming years.
* The expiration of these patents is expected to lead to generic competition in the market.
* The market for OTC allergy medications is expected to grow at a CAGR of 4.5% from 2020 to 2025.
H9. FAQs
1. Q: What are the patents that cover loratadine phenylephrine combinations?
A: The patents that cover loratadine phenylephrine combinations include US Patent 6,455,637, US Patent 6,645,102, and US Patent 7,101,576.
2. Q: When are the patents set to expire?
A: The patents are set to expire in 2024 and 2025.
3. Q: What is the expected impact of generic competition on the market?
A: The entry of generic manufacturers into the market is expected to increase competition and drive prices down.
4. Q: What is the expected growth rate of the market for OTC allergy medications?
A: The market for OTC allergy medications is expected to grow at a CAGR of 4.5% from 2020 to 2025.
5. Q: Who are the generic manufacturers that have filed ANDAs with the FDA?
A: Several generic manufacturers have filed ANDAs with the FDA, but the exact list of manufacturers is not publicly available.
H10. Conclusion
In conclusion, the patents covering loratadine phenylephrine combinations are set to expire in the coming years, leading to generic competition in the market. The expiration of these patents is expected to have a significant impact on the market for OTC allergy medications.
H11. References
* DrugPatentWatch.com. (2022). Loratadine Phenylephrine Combinations.
* Generic Pharmaceutical Association. (2022). Generic Competition in the Market for Loratadine Phenylephrine Combinations.
* Euromonitor International. (2022). OTC Allergy Medications: Global Market Analysis.
H12. About the Author
The author is a pharmaceutical patent analyst with expertise in patent law and pharmaceutical development.
H13. Disclaimer
The information provided in this article is for general information purposes only and should not be considered as professional advice. The author is not a licensed attorney and does not provide legal advice.
H14. Contact Us
For more information, please contact us at [insert contact information].
H15. End of Article
This article has come to an end. Thank you for reading!
Sources:
1. DrugPatentWatch.com. (2022). Loratadine Phenylephrine Combinations.
2. Generic Pharmaceutical Association. (2022). Generic Competition in the Market for Loratadine Phenylephrine Combinations.
3. Euromonitor International. (2022). OTC Allergy Medications: Global Market Analysis.